Comparative Pharmacology
Head-to-head clinical analysis: ANTIVERT versus PROMETHAZINE VC PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIVERT versus PROMETHAZINE VC PLAIN.
ANTIVERT vs PROMETHAZINE VC PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antivert (meclizine) is a piperazine H1 histamine receptor antagonist with central anticholinergic and sedative properties. It suppresses the chemoreceptor trigger zone and labyrinthine apparatus, reducing vestibular stimulation and vertigo.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
25-100 mg orally daily in divided doses 2-4 times daily; maximum 400 mg/day.
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 35–50 hours in adults; prolonged in renal impairment.
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Primarily renal (urine) as unchanged drug and metabolites; biliary excretion is minimal. Approximately 80% excreted unchanged in urine.
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic